FineMark National Bank & Trust Sells 15,412 Shares of Pfizer Inc. (NYSE:PFE)

FineMark National Bank & Trust lessened its position in Pfizer Inc. (NYSE:PFE) by 7.3% in the 4th quarter, Holdings Channel reports. The firm owned 196,586 shares of the biopharmaceutical company’s stock after selling 15,412 shares during the period. FineMark National Bank & Trust’s holdings in Pfizer were worth $5,215,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer in the fourth quarter valued at $32,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of a number of recent analyst reports. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Citigroup dropped their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Down 0.6 %

Pfizer stock opened at $26.13 on Tuesday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business’s fifty day simple moving average is $26.15 and its two-hundred day simple moving average is $27.02. The company has a market capitalization of $148.21 billion, a price-to-earnings ratio of 18.53, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 earnings per share. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.